Xenetic Biosciences (NASDAQ:XBIO) Announces Quarterly Earnings Results, Misses Expectations By $0.48 EPS

Xenetic Biosciences (NASDAQ:XBIO) released its quarterly earnings data on Tuesday. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.48), Zacks reports. The business had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.18 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%.

Xenetic Biosciences Trading Up 3.9 %

Xenetic Biosciences stock opened at $3.60 on Thursday. The company has a market capitalization of $5.54 million, a PE ratio of -1.35 and a beta of 2.17. Xenetic Biosciences has a 12 month low of $2.78 and a 12 month high of $5.20. The stock has a 50-day moving average price of $4.00 and a two-hundred day moving average price of $4.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.